Another potential therapeutic approach for FA was attempted by Hardy et al84; their approach consisted of targeting CD22 on memory B cells with sialic acid–binding Ig-like lectin (SIGLEC)-engaging tolerance-inducing antigenic liposomes (STALs) codisplaying peanut allergens (Ara h 1, Ara h 2, or Ara h 3) and high-affinity CD22 ligand (CD22L-STALs). Here, CD22 is linked to Friedreich ataxia.